ArticleVirology journal2025
Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.Expert review of anti-infective therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeConvalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil.
methodsThis retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements.
resultsPatients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects.
conclusionsOur findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP's mechanisms of action and its integration into broader therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.